<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391025</url>
  </required_header>
  <id_info>
    <org_study_id>145512</org_study_id>
    <secondary_id>NCI-2017-01773</secondary_id>
    <nct_id>NCT02391025</nct_id>
  </id_info>
  <brief_title>Gallium-68 Citrate PET Used in Prostate Cancer</brief_title>
  <official_title>Gallium-68 Citrate PET To Detect MYC Amplification in Metastatic Castrate Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rahul Aggarwal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center cross-sectional imaging study investigating the use of gallium-68&#xD;
      citrate PET in patients with metastatic castration-resistant prostate cancer who are planning&#xD;
      to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519).&#xD;
&#xD;
      The study population will consist of patients with metastatic castration-resistant prostate&#xD;
      cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001&#xD;
      (CC#125519), with evidence of resistance to androgen signaling inhibition.&#xD;
&#xD;
      The study will involve gallium-68 PET scan obtained at single time point, followed by&#xD;
      radiographically-guided metastatic tumor biopsy within 14 days of PET scan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUVmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Mean maximum Standardized Uptake Value (SUV) across all metastatic lesions per patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUVmax-ave</measure>
    <time_frame>Day 1</time_frame>
    <description>Mean maximum Standardized Uptake Value (SUV) across all metastatic lesions across all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between SUVmax and MYC gene expression</measure>
    <time_frame>Day 1</time_frame>
    <description>For patients who undergo optional tumor biopsy, with evaluable RNA sequencing data: Correlation between SUVmax on Gallium-68 Citrate PET and MYC gene expression level, reported as the Pearson correlation coefficient. The coefficient correlation has a value between +1 and -1, where 1 is total positive linear correlation, 0 is no linear correlation, and -1 is total negative linear correlation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between SUVmax and transferrin receptor gene expression</measure>
    <time_frame>Day 1</time_frame>
    <description>For patients who undergo optional tumor biopsy, with evaluable RNA sequencing data: Correlation between SUVmax on Gallium-68 Citrate PET and transferrin receptor gene expression level, reported as the Pearson correlation coefficient. The coefficient correlation has a value between +1 and -1, where 1 is total positive linear correlation, 0 is no linear correlation, and -1 is total negative linear correlation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SUVmax-ave percent change from baseline</measure>
    <time_frame>Within 12 weeks of baseline Gallium-68 Citrate PET</time_frame>
    <description>Mean SUVmax-ave percent change from baseline among patients who undergo optional follow up Gallium-68 Citrate PET following treatment initiation with systemic therapy for Metastatic Castration-Resistant Prostate Cancer (mCRCP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of gallium citrate PET</measure>
    <time_frame>Day 1</time_frame>
    <description>Compared to bone scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of gallium citrate PET</measure>
    <time_frame>Day 1</time_frame>
    <description>Compared to bone scan</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Gallium-68 citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium-68 citrate PET</intervention_name>
    <description>Injection of Gallium-68 citrate followed by PET imaging</description>
    <arm_group_label>Gallium-68 citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <arm_group_label>Gallium-68 citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients with histologically confirmed prostate cancer&#xD;
&#xD;
          -  Patients must have castrate levels of testosterone (&lt; 50 ng/dL) on Luteinizing&#xD;
             hormone-releasing hormone (LHRH) analogue or have had prior bilateral orchiectomy,&#xD;
             with evidence of castration-resistant disease by Prostate Cancer Clinical Trials&#xD;
             Working Group 2 (PCWG2) criteria&#xD;
&#xD;
          -  Age 18 years or older at the time of study entry&#xD;
&#xD;
          -  Minimum of at least three discrete metastatic lesions in the bone and/or soft tissue&#xD;
             amenable to whole body Positron Emission Tomography (PET) imaging per the judgment of&#xD;
             study radiologist&#xD;
&#xD;
        For patients who undergo optional metastatic tumor biopsy following completion of gallium&#xD;
        citrate PET:&#xD;
&#xD;
          -  Presence of one or more metastases by standard radiographic scans that is safely&#xD;
             accessible to tumor biopsy in the judgment of treating clinician and/or Interventional&#xD;
             Radiology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indications to MRI, including permanent pacemaker, implantable device, aneurysm&#xD;
             clip, or severe claustrophobia (for patients planning to be imaged on PET/ Magnetic&#xD;
             resonance imaging(MRI) scanner)&#xD;
&#xD;
          -  Active infection within 14 days of study enrollment&#xD;
&#xD;
        For patients who undergo optional metastatic tumor biopsy following completion of gallium&#xD;
        citrate PET:&#xD;
&#xD;
          -  History of radiation therapy to the target metastatic lesion selected for tumor biopsy&#xD;
&#xD;
          -  Contra-indication to biopsy including uncontrolled bleeding diathesis.&#xD;
&#xD;
          -  Platelets &gt;75,000/Î¼l and prothrombin time (PT) or international normalized ratio (INR)&#xD;
             and a partial prothrombin time (PTT) &lt; 1.5 times the institutional upper limit of&#xD;
             normal (ULN) within 14 days prior to biopsy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul Aggarwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Li</last_name>
    <phone>(415) 476-5975</phone>
    <email>GUTrials@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Li</last_name>
      <phone>415-476-5975</phone>
      <email>GUTrials@ucsf.edu</email>
    </contact>
    <contact_backup>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rahul Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Rahul Aggarwal</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Castrate Resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

